LSA
BDTX icon

Leonteq Securities AG’s Black Diamond Therapeutics BDTX Stock Holding History

Leonteq Securities AG’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,000
Closed -$8.45K – 1298
2022
Q3 		$8.45K Sell
5,000
-5,000
-50% -$15.4K ﹤0.01% 1072
2022
Q2 		$24.6K Buy
10,000
+934
+10% +$2.17K ﹤0.01% 949
2022
Q1 		$25.1K Buy
9,066
+3,066
+51% +$11.2K ﹤0.01% 971
2021
Q4 		$32K Buy
6,000
+5,000
+500% +$34.9K ﹤0.01% 978
2021
Q3 		$8.46K Buy
+1,000
New +$9.88K ﹤0.01% 1058
2021
Q2 		– Sell
-250
Closed -$6.07K – 1070
2021
Q1 		$6.07K Buy
+250
New +$6.74K ﹤0.01% 942

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Leonteq Securities AG's BDTX Position: Q4 2022 in Review

Leonteq Securities AG sold out of Black Diamond Therapeutics (BDTX) in Q4 2022, closing a stake of 5,000 shares — an estimated $8.45K sold.

Leonteq Securities AG first reported a position in BDTX in Q1 2021 and held it in 6 quarters. The position peaked at $32K in Q4 2021. 59 funds tracked by Wall St. Rank hold BDTX as of Q4 2022.

  • Leonteq Securities AG reported no remaining Black Diamond Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Leonteq Securities AG sold 5,000 Black Diamond Therapeutics shares in Q4 2022, an estimated $8.45K.
  • Leonteq Securities AG first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 6 quarters.
  • Leonteq Securities AG's Black Diamond Therapeutics position peaked at $32K in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2022.

Based on Leonteq Securities AG's 13F filing for Q4 2022, filed 26 Mar 2026.